Vaidya Sane Ayurved Laboratories Ltd vs Yatharth Hospital Trauma Care Services Ltd Stock Comparison
Vaidya Sane Ayurved Laboratories Ltd vs Yatharth Hospital Trauma Care Services Ltd Stock Comparison
Last Updated on: Oct 25, 2026
Key Highlights
The Latest Trading Price of Vaidya Sane Ayurved Laboratories Ltd is ₹ 146.45 as of 23 Oct 15:30
. The P/E Ratio of Vaidya Sane Ayurved Laboratories Ltd changed from 51.1 on March 2023 to 0 on March 2022 . This represents a CAGR of -100.00% over 6 yearsThe P/E Ratio of Yatharth Hospital & Trauma Care Services Ltd changed from 31.3 on March 2024 to 0 on March 2022 . This represents a CAGR of -100.00% over 5 years The Market Cap of Vaidya Sane Ayurved Laboratories Ltd changed from ₹ 247.07 crore on March 2023 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 6 yearsThe Market Cap of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 3582 crore on March 2024 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 5 years The revenue of Vaidya Sane Ayurved Laboratories Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Yatharth Hospital & Trauma Care Services Ltd for the Jun '26 is ₹ 397.01 crore as compare to the Mar '26 revenue of ₹ 348.67 crore. This represent the growth of 13.86% The ebitda of Vaidya Sane Ayurved Laboratories Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Yatharth Hospital & Trauma Care Services Ltd for the Jun '26 is ₹ 96.04 crore as compare to the Mar '26 ebitda of ₹ 87.02 crore. This represent the growth of 10.37% The net profit of Vaidya Sane Ayurved Laboratories Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0%
The net profit of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 30.38 crore to ₹ 45.42 crore over 9 quarters. This represents a CAGR of 19.57%
The Dividend Payout of Vaidya Sane Ayurved Laboratories Ltd changed from 5.06 % on March 2023 to 0 % on March 2026 . This represents a CAGR of -100.00% over 4 yearsThe Dividend Payout of Yatharth Hospital & Trauma Care Services Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .
About Vaidya Sane Ayurved Laboratories Ltd
Vaidya Sane Ayurved Laboratories Limited was originally incorporated as a Private Limited Company pursuant to a Certificate of Incorporation issued by the Registrar of Companies, Pune dated April 6, 1999 with the name Vaidya Sane Ayurved Laboratories Private Limited'.
Subsequently, Company was converted into to a Public Limited Company and the name of Company was changed to Vaidya Sane Ayurved Laboratories Limited'.
A fresh Certificate of Incorporation upon conversion was issued on November 25, 2021 by the Registrar of Companies, Pune.
The Company is a unique medical service institution to treat chronic ailments like cardiac disease, diabetes, hypertension and obesity with the distinctive outlook of amalgamating technology with traditional healing of Ayurveda.
Its approach to treatment using non-invasive, multidisciplinary and innovative therapies has helped the Company for treating the chronic ailments.
About Yatharth Hospital & Trauma Care Services Ltd
Yatharth Hospital & Trauma Care Services Limited was formerly incorporated as a Private Limited Company in Delhi dated February 28, 2008.
On November 3, 2021, the status converted into a Public Company and name of the Company was changed to Yatharth Hospital & Trauma Care Services Limited' on November 18, 2021 issued by the RoC.
Yatharth Hospitals and Trauma Care Services Limited is a network of super speciality hospitals across Delhi National Capital Region (NCR) and Madhya Pradesh, capitalising on the robust healthcare infrastructure in these regions to serve a wide patient base in need of tertiary care.
The Company operate three super specialty hospitals in Delhi NCR, i.e., at Greater Noida, Uttar Pradesh.
The super speciality tertiary care
hospital currently operates with 400 beds, including 112 critical care beds and 9 modular operation theatres, among other surgical facilities.
FAQs for the comparison of Vaidya Sane Ayurved Laboratories Ltd and Yatharth Hospital & Trauma Care Services Ltd
Which company has a larger market capitalization, Vaidya Sane Ayurved Laboratories Ltd or Yatharth Hospital & Trauma Care Services Ltd?
Market cap of Vaidya Sane Ayurved Laboratories Ltd is 153 Cr while Market cap of Yatharth Hospital & Trauma Care Services Ltd is 8,978 Cr
What are the key factors driving the stock performance of Vaidya Sane Ayurved Laboratories Ltd and Yatharth Hospital & Trauma Care Services Ltd?
The stock performance of Vaidya Sane Ayurved Laboratories Ltd and Yatharth Hospital & Trauma Care Services Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Vaidya Sane Ayurved Laboratories Ltd and Yatharth Hospital & Trauma Care Services Ltd?
As of October 25, 2026, the Vaidya Sane Ayurved Laboratories Ltd stock price is INR ₹146.45. On the other hand, Yatharth Hospital & Trauma Care Services Ltd stock price is INR ₹931.85.
How do dividend payouts of Vaidya Sane Ayurved Laboratories Ltd and Yatharth Hospital & Trauma Care Services Ltd compare?
To compare the dividend payouts of Vaidya Sane Ayurved Laboratories Ltd and Yatharth Hospital & Trauma Care Services Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.